Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tracks odevixibat safety in pregnant and nursing women

NCT ID NCT06258902

Recruiting now Knowledge-focused Sponsor: Ipsen Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times

Summary

This study watches for any health problems in pregnant or breastfeeding women who have taken the drug odevixibat, and in their babies. It does not give any new treatments or tests—just collects information from regular doctor visits. About 20 people will take part to help understand if the drug is safe during pregnancy and nursing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY RELATED are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Virtual Research Coordination Center Odevixibat (BYLVAY) Pregnancy Surveillance Program

    RECRUITING

    Wilmington, North Carolina, 28401, United States

Conditions

Explore the condition pages connected to this study.